These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25175311)

  • 1. Chemical biology approaches to target validation in cancer.
    Blagg J; Workman P
    Curr Opin Pharmacol; 2014 Aug; 17():87-100. PubMed ID: 25175311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is target validation all we need?
    Frigault MM; Barrett JC
    Curr Opin Pharmacol; 2014 Aug; 17():81-6. PubMed ID: 25261632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.
    Poornima P; Kumar JD; Zhao Q; Blunder M; Efferth T
    Pharmacol Res; 2016 Sep; 111():290-302. PubMed ID: 27329331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 5. Recently targeted kinases and their inhibitors-the path to clinical trials.
    Knapp S; Sundström M
    Curr Opin Pharmacol; 2014 Aug; 17():58-63. PubMed ID: 25113945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
    Choe H; Ruan J
    Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and potential clinical utility of biomarkers for HDAC inhibitors.
    Shi B; Xu W
    Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in targeting signal transduction pathways.
    McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
    Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
    Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data.
    Tkachev V; Sorokin M; Garazha A; Borisov N; Buzdin A
    Methods Mol Biol; 2020; 2063():235-255. PubMed ID: 31667774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking 'academic' drug discovery: the Manchester Institute perspective.
    Jordan AM; Waddell ID; Ogilvie DJ
    Drug Discov Today; 2015 May; 20(5):525-35. PubMed ID: 25542353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity-oriented synthetic strategies applied to cancer chemical biology and drug discovery.
    Collins I; Jones AM
    Molecules; 2014 Oct; 19(11):17221-55. PubMed ID: 25350364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer epigenetics drug discovery and development: the challenge of hitting the mark.
    Campbell RM; Tummino PJ
    J Clin Invest; 2014 Jan; 124(1):64-9. PubMed ID: 24382391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting receptor tyrosine kinase co-activation for cancer therapy.
    Tan AC; Vyse S; Huang PH
    Drug Discov Today; 2017 Jan; 22(1):72-84. PubMed ID: 27452454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of mTOR in aging and cancer.
    Zhavoronkov A
    Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.